FDA Fast Tracks Acadia's Remlifanserin for Alzheimer's Psychosis; Phase 2 Data Due by October
ACAD sits 30% above its 52-week low of $19.69.
Summary
The FDA granted Fast Track designation to remlifanserin for Alzheimer's disease psychosis, a condition with no approved therapies. This regulatory milestone accelerates development and review, and follows a positive EMA opinion for Daybue in June. Enrollment in the Phase 2 RADIANT trial is complete, with topline results now expected between September and October 2026—a concrete near-term catalyst. Phase 3 screening is already underway, signaling confidence in the program. The news adds a clear value driver to Acadia's pipeline beyond its commercial products.
At the time of this announcement, ACAD was trading at $25.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $19.69 to $28.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.